ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,117.52
      -0.43%
      US Tech 100
      21,490.80
      -0.42%
      Dow Jones
      44,176.65
      -1.01%
      Brent Oil
      76.105
      -0.26%
      Bitcoin
      98,187.80
      -0.13%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. I MAB (IMAB)

      7. I MAB (IMAB) News

      I MAB

      I MAB (IMAB)

      NASDAQ
      0.9667
      -0.0033
      (-0.34%)
      Closed February 20 4:00PM
      Delayed by 15 minutes
      0.95
      -0.0167
      (-1.73%)
      After Hours: 7:20PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      IMAB News

      Official News Only

      Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
      Edgar (US Regulatory)
      February 05 2025
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 29 2025
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 13 2025
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 08 2025
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 06 2025
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      November 14 2024
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      November 06 2024
      IMAB (-0.34%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      November 05 2024
      IMAB (-0.34%)

      IMAB Discussion

      View Posts
      glenn1919 glenn1919 4 months ago
      IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 6 months ago
      IMAB under $2
      👍️0
      Monksdream Monksdream 7 months ago
      IMAB under $2
      👍️0
      Monksdream Monksdream 8 months ago
      IMAB under $2
      👍️0
      stock1ace1 stock1ace1 10 months ago
      Imab $1.80 golden cross https://schrts.co/CNBigxhc

      I-Mab Price Target Maintained With a $6.00/Share by Needham
      Mentioned: IMAB

      Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

      (END) Dow Jones Newswires

      April 12, 2024 06:15 ET (10:15 GMT)
      👍️0
      Monksdream Monksdream 11 months ago
      IMAB 10Q due 4/3
      👍️0
      Monksdream Monksdream 11 months ago
      IMAB under $2=
      👍️0
      Monksdream Monksdream 11 months ago
      IMAB under $2
      👍️0
      Monksdream Monksdream 1 year ago
      IMAB under $2
      👍️0
      AGORDON AGORDON 1 year ago
      IMAB
      This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?
      👍️0
      AGORDON AGORDON 1 year ago
      2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.
      👍️0
      AGORDON AGORDON 1 year ago
      Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.
      👍️0
      AGORDON AGORDON 1 year ago
      Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.
      👍️0
      AGORDON AGORDON 1 year ago
      From the 20-F report

      On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.
      👍️0
      AGORDON AGORDON 1 year ago
      In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.
      👍️0
      AGORDON AGORDON 1 year ago
      The stock has bounced off $1.80 two times within a month.
      👍️0
      AGORDON AGORDON 1 year ago
      Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.
      👍️0
      Mt. Blanc Mt. Blanc 1 year ago
      IMAB climbing the charts tracking the $3s. Check it out soon.

      mb
      👍️0
      Monksdream Monksdream 1 year ago
      IMAB under $2
      👍️0

      Your Recent History

      NASDAQ
      IMAB
      I MAB
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads